Collaboration offers clients more streamlined and efficient approach to clinical trial planning
ST. LOUIS, MO and HOLLISTON, MA – May 14, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, and Veristat, LLC., a leading full service clinical research organization, today announced that they have formed an alliance to offer combined services to their clients. The joint service offering includes: Pharmacokinetic (PK) analysis, PK /Pharmacodynamic (PD) modeling, population PK modeling, trial simulation, clinical biostatistics, medical writing, data management, clinical monitoring, safety management, and project management. These combined services will help streamline the drug discovery, development and trial planning processes by improving the efficiency of data collection and analysis and enabling clients to procure value-added services through their existing vendor relationship.
“We look forward to offering Certara’s capabilities to our clients,” said Patrick Flanagan, chief business officer of Veristat. “Their Pharsight Consulting Services team is a world-class organization in the modeling and simulation of drugs and diseases. By combining our core services with their insight and experience, Veristat broadens our delivery platform and is able to more immediately respond to our clients’ outsourcing needs. The benefit to our clients is greater overall efficiency, impact and probability of success for their clinical trial programs.”
“We are pleased to partner with Veristat to expand what we can offer to clients as they seek to streamline their outsourcing of critical tasks in trial planning, analysis, and reporting,” said Daniel Weiner, Chief Technology Officer and head of Certara’s scientific consulting services. “Veristat specializes in several trial services that lie outside our core domain, and together we can offer more to the client than either organization could alone.”
Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp®, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit http://www.certara.com.
Veristat, Inc. is an innovative, science-focused clinical research organization (CRO) in its 20th year of providing dynamic expertise in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive services, including biostatistics, statistical programming, medical writing, clinical monitoring and data management for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information about Veristat and the services provided please visit http://www.veristat.com.
Diana O’Rourke, 314-951-3310
Director of Marketing